Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037957 | 1.00 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2197708 | 0.80 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL1965663 | 0.78 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL423782 | 0.75 | CA2 (0.43) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2677860 | 0.75 | ALDH1A1 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL8951223 | 0.75 | ALDH1A1 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL9396214 | 0.75 | CA2 (0.59) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2561632 | 0.75 | CA2 (0.80) | CA2CA12CA1CA9CHKA | |
| SCHEMBL103468 | 0.72 | ALDH1A1 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL10791 | 0.72 | ALDH1A1 (0.52) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100410-A1 | IODINE-CONTAINING POLYMERIZABLE COMPOUND AND IODINE-CONTAINING POLYMER | 三菱瓦斯化学株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| EP-3686188-B1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3892278-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113164481-A | Cycloalkane-1, 3-diamine derivatives | 第一三共株式会社 | 2021-07-23 | — | — | CN | disclosed |
| US-6211215-B1 | AROMATIC HETEROCYCLIC COMPOUND WITH AZOLE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| US-5972959-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0912562-A1 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1999-05-06 | — | — | EP | disclosed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | disclosed |
| US-5780490-A | A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS | SANKYO COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| WO-1998003505-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | CA2 3061/4885CA12 4376/4885CA1 3083/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | CA2 3061/4885CA12 4376/4885CA1 3083/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | CA2 3061/4885CA12 4376/4885CA1 3083/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | CA2 1207/4885CA12 2699/4885CA1 961/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | CA2 3061/4885CA12 4376/4885CA1 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.